Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Sherris

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The American Journal of Pathology|September 18, 2012
Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitorFarhatullah Syed, David Sherris, Ralf Paus, et al.
Investigative Ophthalmology & Visual Science|April 17, 2009
Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathwayGeoffrey P Lewis, Ethan A Chapin, Jiyun Byun, et al.
Therapeutics and Clinical Risk Management|March 25, 2008
Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin BEugene B Kern, David Sherris, Angelos M Stergiou, et al.
Endocrine-Related Cancer|May 10, 2011
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cellsGiovanni Luca Gravina, Francesco Marampon, Foteini Petini, et al.
The Prostate|April 10, 2014
Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer modelsGiovanni Luca Gravina, Francesco Marampon, David Sherris, et al.
Cancers|December 31, 2025
RETRACTED: Gravina et al. The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. <i>Cancers</i> 2019, <i>11</i>, 1604Giovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Cancers|October 24, 2019
The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine ModelsGiovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Nature Communications|November 28, 2013
RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcriptionDamien Gerald, Irit Adini, Sharon Shechter, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The American Journal of Pathology|September 18, 2012
Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitorFarhatullah Syed, David Sherris, Ralf Paus, et al.
Investigative Ophthalmology & Visual Science|April 17, 2009
Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathwayGeoffrey P Lewis, Ethan A Chapin, Jiyun Byun, et al.
Therapeutics and Clinical Risk Management|March 25, 2008
Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin BEugene B Kern, David Sherris, Angelos M Stergiou, et al.
Endocrine-Related Cancer|May 10, 2011
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cellsGiovanni Luca Gravina, Francesco Marampon, Foteini Petini, et al.
The Prostate|April 10, 2014
Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer modelsGiovanni Luca Gravina, Francesco Marampon, David Sherris, et al.
Cancers|December 31, 2025
RETRACTED: Gravina et al. The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. <i>Cancers</i> 2019, <i>11</i>, 1604Giovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Cancers|October 24, 2019
The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine ModelsGiovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Nature Communications|November 28, 2013
RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcriptionDamien Gerald, Irit Adini, Sharon Shechter, et al.
Pageof 2